FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Pekka Lähteenmäki

Research Profile

Chemicals & Drugs

Devices

Physiology

Concepts & Ideas

Time Factors

Co-author Network

Publications

TOP 3
Janina Kaislasuo; Pekka Lähteenmäki; Satu Suhonen; Mika Gissler; Oskari Heikinheimo
Uterine perforation caused by intrauterine devices: clinical course and treatment.
Janina Kaislasuo; Pekka Lähteenmäki; Satu Suhonen; Mika Gissler; Oskari Heikinheimo
Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study.
Oskari Heikinheimo; Pekka Lähteenmäki
Contraception and HIV infection in women.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Pekka Lähteenmäki (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Janina Kaislasuo; Pekka Lähteenmäki; Satu Suhonen; Mika Gissler; Oskari Heikinheimo
Uterine perforation caused by intrauterine devices: clinical course and treatment.
Human reproduction (Oxford, England) 2013;28(6):1546-51.
2012: Janina Kaislasuo; Pekka Lähteenmäki; Satu Suhonen; Mika Gissler; Oskari Heikinheimo
Intrauterine contraception: incidence and factors associated with uterine perforation--a population-based study.
Human reproduction (Oxford, England) 2012;27(9):2658-63.
2009: Oskari Heikinheimo; Pekka Lähteenmäki
Contraception and HIV infection in women.
Human reproduction update 2009;15(2):165-76.
2005: Irving Sivin; Daniel R Mishell; Francisco Alvarez; Vivian Brache; Kaisa Elomaa; Pekka Lähteenmäki; Rebeca Massai; Patricia Miranda; Horacio B Croxatto; Catherine Dean; Margaret Small; Harold A Nash; Theodore M Jackanicz
Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.
Contraception 2005;71(2):122-9.
2003: Oskari Heikinheimo; Raimo Kekkonen; Pekka Lähteenmäki
The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action.
Contraception 2003;68(6):421-6.
2003: Kaija Ylänen; Timo Laatikainen; Pekka Lähteenmäki; Alfred Moo-Young
Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses.
Acta obstetricia et gynecologica Scandinavica 2003;82(2):167-72.
2001: Leena Christiansen; Pekka Lähteenmäki; M R Mannelin; Tuulikki Seppänen-Laakso; Raimo Hiltunen; Jouko Yliruusi
Cholesterol-lowering effect of spreads enriched with microcrystalline plant sterols in hypercholesterolemic subjects.
European journal of nutrition 2001;40(2):66-73.
2001: Kaisa Elomaa; Sirpa Ranta; J Tuominen; Pekka Lähteenmäki
The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
Contraception 2001;63(1):13-8.
2001: Kaisa Elomaa; Sirpa Ranta; J Tuominen; Pekka Lähteenmäki
Charcoal treatment and risk of escape ovulation in oral contraceptive users.
Human reproduction (Oxford, England) 2001;16(1):76-81.
2000: Vivian Brache; F Alvarez-Sanchez; Anibal Faundes; Theodore M Jackanicz; Daniel R Mishell; Pekka Lähteenmäki
Progestin-only contraceptive rings.
Steroids 2000;65(10-11):687-91.
2000: Ian S Fraser; MD Lacarra; Daniel R Mishell; Francisco Alvarez; Vivian Brache; Pekka Lähteenmäki; Kaisa Elomaa; Edith Weisberg; Harold A Nash
Vaginal epithelial surface appearances in women using vaginal rings for contraception.
Contraception 2000;61(2):131-8.
1999: J Suvisaari; Alfred Moo-Young; A Juhakoski; Kaisa Elomaa; S I Saleh; Pekka Lähteenmäki
Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men.
Contraception 1999;60(5):299-303.
1999: Kaisa Elomaa; Pekka Lähteenmäki
Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
Contraception 1999;60(5):275-9.
1999: G Noé; J Suvisaari; C Martin; Alfred Moo-Young; Kalyan Sundaram; S I Saleh; E Quintero; Horacio B Croxatto; Pekka Lähteenmäki
Gonadotrophin and testosterone suppression by 7alpha-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men.
Human reproduction (Oxford, England) 1999;14(9):2200-6.
1999: Oskari Heikinheimo; Sirpa Ranta; Alfred Moo-Young; Pekka Lähteenmäki; K Gordon
Parenteral administration of progestin Nestorone to lactating cynomolgus monkeys: an ideal hormonal contraceptive at lactation?
Human reproduction (Oxford, England) 1999;14(8):1993-7.
1999: Ian S Fraser; Pekka Lähteenmäki; Kaisa Elomaa; MD Lacarra; Daniel R Mishell; Francisco Alvarez; Vivian Brache; Edith Weisberg; Martha Hickey; P Vallentine; Harold A Nash
Variations in vaginal epithelial surface appearance determined by colposcopic inspection in healthy, sexually active women.
Human reproduction (Oxford, England) 1999;14(8):1974-8.
1998: Päivi Pakarinen; Pekka Lähteenmäki; Eero Lehtonen; I Reima
The ultrastructure of human endometrium is altered by administration of intrauterine levonorgestrel.
Human reproduction (Oxford, England) 1998;13(7):1846-53.
1998: Kaisa Elomaa; R Rolland; I Brosens; M Moorrees; J Deprest; J Tuominen; Pekka Lähteenmäki
Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
American journal of obstetrics and gynecology 1998;179(1):41-6.
1998: Mirja Puolakkainen; Eija Hiltunen-Back; Timo Reunala; Satu Suhonen; Pekka Lähteenmäki; M Lehtinen; Jorma Paavonen
Comparison of performances of two commercially available tests, a PCR assay and a ligase chain reaction test, in detection of urogenital Chlamydia trachomatis infection.
Journal of clinical microbiology 1998;36(6):1489-93.
1998: Pekka Lähteenmäki; Maija Haukkamaa; J Puolakka; U Riikonen; S Sainio; J Suvisaari; C G Nilsson
Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy.
BMJ (Clinical research ed.) 1998;316(7138):1122-6.
1997: Christopher J Elias; Christiana Coggins; Francisco Alvarez; Vivian Brache; Ian S Fraser; MD Lacarra; Pekka Lähteenmäki; Rebeca Massai; Daniel R Mishell; D M Phillips; Ana Maria Salvatierra
Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan.
Contraception 1997;56(6):387-9.
1997: Irving Sivin; Pekka Lähteenmäki; Daniel R Mishell; Francisco Alvarez; S Diaz; Sirpa Ranta; C Grozinger; MD Lacarra; Vivian Brache; Margarita Pavez; Harold A Nash; J Stern
First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants.
Contraception 1997;56(5):317-21.
1997: Päivi Pakarinen; J Suvisaari; Tapani Luukkainen; Pekka Lähteenmäki
Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Fertility and sterility 1997;68(1):59-64.
1997: J Suvisaari; Kalyan Sundaram; G Noé; Narender Kumar; C Aguillaume; Yun-Yen Tsong; Pekka Lähteenmäki; CW Bardin
Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men.
Human reproduction (Oxford, England) 1997;12(5):967-73.
1997: Oskari Heikinheimo; Sirpa Ranta; Steven M Grunberg; Pekka Lähteenmäki; I M Spitz
Alterations in the pituitary-thyroid and pituitary-adrenal axes--consequences of long-term mifepristone treatment.
Metabolism: clinical and experimental 1997;46(3):292-6.
1997: Irving Sivin; Pekka Lähteenmäki; Sirpa Ranta; Philip D Darney; C Klaisle; L Wan; Daniel R Mishell; MD Lacarra; OA Viegas; P Bilhareus; S Koetsawang; Manee Piya-Anant; S Diaz; Margarita Pavez; Francisco Alvarez; Vivian Brache; K LaGuardia; Harold A Nash; J Stern
Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants.
Contraception 1997;55(2):81-5.
1997: Satu Suhonen; T Holmström; Pekka Lähteenmäki
Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy.
Acta obstetricia et gynecologica Scandinavica 1997;76(2):145-50.
1997: Pekka Lähteenmäki
[Post-coital contraception].
Duodecim; lääketieteellinen aikakauskirja 1997;113(12):1187-92.
1997: Pekka Lähteenmäki
[From contraception to treatment of sexual health].
Duodecim; lääketieteellinen aikakauskirja 1997;113(12):1157-8.
1997: Pekka Lähteenmäki; CW Bardin; Kaisa Elomaa; Maija Haukkamaa; A Kivijärvi; A Kuukankorpi; M Venhola; J Tuominen
Selection and performance of the levonorgestrel-releasing intrauterine system.
Acta obstetricia et gynecologica Scandinavica. Supplement 1997;164():69-74.
1996: R Kekkonen; Oskari Heikinheimo; E Mandelin; Pekka Lähteenmäki
Pharmacokinetics of mifepristone after low oral doses.
Contraception 1996;54(4):229-34.
1996: J Suvisaari; Pekka Lähteenmäki
Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
Contraception 1996;54(4):201-8.
1996: Päivi Pakarinen; Tapani Luukkainen; Kaisa Elomaa; K Ratsula; P Venesmaa; J Tuominen; Pekka Lähteenmäki
A 12-month comparative clinical investigation of a levonorgestrel-releasing intracervical device situated in the uterine cavity or cervical canal.
Contraception 1996;54(3):187-92.
1996: R Kekkonen; Pekka Lähteenmäki
Cyclic progestin administration brings about luteinization during continuous antiprogestin treatment.
Contraception 1996;53(4):193-5.
1996: Satu Suhonen; Maija Haukkamaa; T Holmström; Pekka Lähteenmäki; E M Rutanen
Endometrial response to hormone replacement therapy as assessed by expression of insulin-like growth factor-binding protein-1 in the endometrium.
Fertility and sterility 1996;65(4):776-82.
1995: Päivi Pakarinen; Tapani Luukkainen; H Laine; Pekka Lähteenmäki
The effect of local intrauterine levonorgestrel administration on endometrial thickness and uterine blood circulation.
Human reproduction (Oxford, England) 1995;10(9):2390-4.
1995: Satu Suhonen; H O Allonen; Pekka Lähteenmäki
Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy.
American journal of obstetrics and gynecology 1995;172(2 Pt 1):562-7.
1995: Satu Suhonen; T Holmström; H O Allonen; Pekka Lähteenmäki
Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy.
Fertility and sterility 1995;63(2):336-42.
1995: R Kekkonen; H B Croxatto; Pekka Lähteenmäki; Ana Maria Salvatierra; J Tuominen
Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation.
Human reproduction (Oxford, England) 1995;10(2):287-92.
1995: Soledad Díaz; V Schiappacasse; Margarita Pavez; Ana Zepeda; Alfred Moo-Young; A Brandeis; Pekka Lähteenmäki; Horacio B Croxatto
Clinical trial with Nestorone subdermal contraceptive implants.
Contraception 1995;51(1):33-8.
1994: Oskari Heikinheimo; G Noe; Maija Haukkamaa; Pekka Lähteenmäki
The progestin ST 1435--rapid metabolism in man.
Contraception 1994;50(3):275-89.
1994: I M Spitz; H B Croxatto; Pekka Lähteenmäki; Oskari Heikinheimo; CW Bardin
Effect of mifepristone on inhibition of ovulation and induction of luteolysis.
Human reproduction (Oxford, England) 1994;9 Suppl 1():69-76.
1994: Oskari Heikinheimo; Ullamari Pesonen; R Huupponen; Markku Koulu; Pekka Lähteenmäki
Hepatic metabolism and distribution of mifepristone and its metabolites in rats.
Human reproduction (Oxford, England) 1994;9 Suppl 1():40-6.
1993: Satu Suhonen; H O Allonen; Pekka Lähteenmäki
Sustained-release subdermal estradiol implants: a new alternative in estrogen replacement therapy.
American journal of obstetrics and gynecology 1993;169(5):1248-54.
1993: R Kekkonen; Pekka Lähteenmäki; Tapani Luukkainen; J Tuominen
Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Fertility and sterility 1993;60(4):610-5.
1993: Pekka Lähteenmäki
Postabortal contraception.
Annals of medicine 1993;25(2):185-9.
1993: Satu Suhonen; S Sipinen; Pekka Lähteenmäki; H Laine; J Rainio; H Arko
Postmenopausal oestrogen replacement therapy with subcutaneous oestradiol implants.
Maturitas 1993;16(2):123-31.
1992: M Laurikka-Routti; Maija Haukkamaa; Pekka Lähteenmäki
Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Fertility and sterility 1992;58(4):680-4.
1992: Satu Suhonen; Maija Haukkamaa; Pekka Lähteenmäki; T Holmström
Endometrial effect of transdermal estradiol and progestin ST-1435 in postmenopausal women.
Fertility and sterility 1992;57(6):1211-5.
1992: K J Huovinen; Pekka Lähteenmäki; J Kärkkäinen; Matti J Tikkanen
Lynestrenol induced therapeutic amenorrhea: effects of dose reduction on serum sex-hormones and lipids.
Acta obstetricia et gynecologica Scandinavica 1992;71(3):175-80.
1991: Pekka Lähteenmäki; Rochelle N Shain; K Ratsula; Juhani Toivonen; Alan EC Holden; M Rosenthal; Tapani Luukkainen
[One year experience of levonorgestrel-releasing intrauterine device].
Duodecim; lääketieteellinen aikakauskirja 1991;107(1):26-31.
1990: P L Lähteenmäki; S Diaz; Patricia Miranda; H Croxatto; Pekka Lähteenmäki
Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435.
Contraception 1990;42(5):555-62.
1990: Oskari Heikinheimo; Olavi Ylikorkala; Ursula Turpeinen; Pekka Lähteenmäki
Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486.
Acta endocrinologica 1990;123(3):298-304.
1990: Outi Hovatta; H Kurunmäki; A Tiitinen; Pekka Lähteenmäki; A I Koskimies
Direct intraperitoneal or intrauterine insemination and superovulation in infertility treatment: a randomized study.
Fertility and sterility 1990;54(2):339-41.
1990: Oskari Heikinheimo; Olavi Ylikorkala; Pekka Lähteenmäki
Antiprogesterone RU 486--a drug for non-surgical abortion.
Annals of medicine 1990;22(2):75-84.
1990: Tapani Luukkainen; Pekka Lähteenmäki; Juhani Toivonen
Levonorgestrel-releasing intrauterine device.
Annals of medicine 1990;22(2):85-90.
1990: R Kekkonen; Henrik Alfthan; Maija Haukkamaa; Oskari Heikinheimo; Tapani Luukkainen; Pekka Lähteenmäki
Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Fertility and sterility 1990;53(4):747-50.
1989: Olavi Ylikorkala; Henrik Alfthan; M Kääriäinen; T Rapeli; Pekka Lähteenmäki
Outpatient therapeutic abortion with mifepristone.
Obstetrics and gynecology 1989;74(4):653-7.
1989: Oskari Heikinheimo; Maija Haukkamaa; Pekka Lähteenmäki
Distribution of RU 486 and its demethylated metabolites in humans.
The Journal of clinical endocrinology and metabolism 1989;68(2):270-5.
1989: K Ratsula; Juhani Toivonen; Pekka Lähteenmäki; Tapani Luukkainen
Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Contraception 1989;39(2):195-204.
1989: Rochelle N Shain; K Ratsula; Juhani Toivonen; Pekka Lähteenmäki; Tapani Luukkainen; Alan EC Holden; M Rosenthal
Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
Contraception 1989;39(1):73-84.
1988: Pekka Lähteenmäki; T Rapeli; M Kääriäinen; Henrik Alfthan; Olavi Ylikorkala
Late postcoital treatment against pregnancy with antiprogesterone RU 486.
Fertility and sterility 1988;50(1):36-8.
1988: Tapani Luukkainen; Oskari Heikinheimo; Maija Haukkamaa; Pekka Lähteenmäki
Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Fertility and sterility 1988;49(6):961-3.
1987: Oskari Heikinheimo; H Croxatto; Ana Maria Salvatierra; C C Chang; Tapani Luukkainen; Pekka Lähteenmäki
Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans.
Human reproduction (Oxford, England) 1987;2(8):645-8.
1987: Oskari Heikinheimo; Pekka Lähteenmäki; Erkki Koivunen; D Shoupe; H Croxatto; Tapani Luukkainen; P Lähteenmäki
Metabolism and serum binding of RU 486 in women after various single doses.
Human reproduction (Oxford, England) 1987;2(5):379-85.
1987: Oskari Heikinheimo; K Kontula; H Croxatto; I Spitz; Tapani Luukkainen; Pekka Lähteenmäki
Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
Journal of steroid biochemistry 1987;26(2):279-84.
1987: Pekka Lähteenmäki; Oskari Heikinheimo; H Croxatto; I Spitz; D Shoupe; L Birgerson; Tapani Luukkainen
Pharmacokinetics and metabolism of RU 486.
Journal of steroid biochemistry 1987;27(4-6):859-63.
1986: Oskari Heikinheimo; M Tevilin; D Shoupe; H Croxatto; Pekka Lähteenmäki
Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography.
Contraception 1986;34(6):613-24.
1986: Tapani Luukkainen; H Allonen; Maija Haukkamaa; Pekka Lähteenmäki; C G Nilsson; Juhani Toivonen
Five years' experience with levonorgestrel-releasing IUDs.
Contraception 1986;33(2):139-48.
1985: H Kurunmäki; Juhani Toivonen; Pekka Lähteenmäki; Tapani Luukkainen
Contraception with subdermal ST-1435 capsules: side-effects, endocrine profiles and liver function related to different lengths of capsules.
Contraception 1985;31(3):305-18.
1984: H Kurunmäki; Juhani Toivonen; Pekka Lähteenmäki; Tapani Luukkainen
Immediate postabortal contraception with Norplant: levonorgestrel, gonadotropin, estradiol, and progesterone levels over two postabortal months and return of fertility after removal of Norplant capsules.
Contraception 1984;30(5):431-42.
1984: Pekka Lähteenmäki; H Kurunmäki; P Lähteenmäki; Juhani Toivonen; Tapani Luukkainen
Pharmacokinetic observations on ST-1435 administered subcutaneously and intravaginally.
Contraception 1984;30(4):381-9.
1984: H Kurunmäki; Juhani Toivonen; Pekka Lähteenmäki; Tapani Luukkainen
Intracervical release of ST-1435 for contraception.
Contraception 1984;29(5):411-21.
1984: H Kurunmäki; Juhani Toivonen; Pekka Lähteenmäki; Tapani Luukkainen
Pituitary and ovarian function and clinical performance during the use of a levonorgestrel-releasing intracervical contraceptive device.
Contraception 1984;29(1):31-43.
1983: P Lähteenmäki; Juhani Toivonen; Pekka Lähteenmäki
Postabortal contraception with norethisterone enanthate injections.
Contraception 1983;27(6):553-62.
1982: C G Nilsson; Pekka Lähteenmäki; Maija Haukkamaa
Diagnostic value of a rapid HCG-beta-subunit radioimmunoassay in cases of suspected ectopic pregnancies.
International journal of fertility 1982;27(1):36-41.
1981: H Kurunmäki; Juhani Toivonen; Pekka Lähteenmäki; Tapani Luukkainen
Intracervical release of levonorgestrel for contraception.
Contraception 1981;23(5):473-85.
1980: S Sipinen; Pekka Lähteenmäki; Tapani Luukkainen
An oestrone-releasing vaginal ring in the treatment of climacteric women.
Maturitas 1980;2(4):291-9.
1980: S Sipinen; Pekka Lähteenmäki
Steroid and gonadotropin profiles in menopausal women on three different oral replacement regimens.
Annals of clinical research 1980;12(6):282-7.
1980: S Sipinen; Pekka Lähteenmäki; Tapani Luukkainen
Silastic implants releasing estrone in the treatment of climacteric complaints.
Maturitas 1980;2(3):213-24.
1980: Pekka Lähteenmäki; P Ylöstalo; S Sipinen; Juhani Toivonen; L Ruusuvaara; P Pikkola; C G Nilsson; Tapani Luukkainen
Return of ovulation after abortion and after discontinuation of oral contraceptives.
Fertility and sterility 1980;34(3):246-9.
1980: S Sipinen; Pekka Lähteenmäki; Tapani Luukkainen
Pharmacokinetic studies on low dose estradiol 17 beta administered orally to postmenopausal women.
Acta obstetricia et gynecologica Scandinavica 1980;59(2):149-53.